The Risk With Too Little Or Too Much Sleep
A study led by Femke Rutters has found that too much or too less sleep can increase the future risk of type 2 diabetes (T2D). This phenomenon is associated only in men.
The researchers have observed the sleep duration and the risk factors for diabetes in 788 people, aged between 30 and 60 years, from 14 European countries.
The study has found that those men who slept the least time or long time had an increased risk of inability to process the glucose present in the bloodstream and they are at the higher blood sugar (glucose) levels. Healthy sleep duration is between 7.5 and 9 hours.
Femke Rutters, VU University Medical Center, Amsterdam is the senior author of the study. The study was published in the Journal of the Clinical Endocrinology & Metabolism.
Treatment With The Diabetes Drug Pioglitazone For NASH
A three-year-long study published in the Annals of Internal Medicine has found a treatment for NASH (a fatty liver disease, nonalcoholic steatohepatitis) in patients with diabetes.
The study has offered the diabetes drug Pioglitazone for the treatment of NASH in a patient with diabetes. The study has found that 58 percent of the participants of the study can able to lower the NASH and 51 percent of people are without NASH.
The Diplomat specialty pharmacy is expecting approval for the drug in 2016 and the treatment may start in 2017.
The Treatment For The Diabetic Macular Edema (DME) With The Bevacizumab Injection
The macula, a part of the retina can give us the most detailed vision abilities. The high blood sugar (glucose) levels in a patient of type 2 diabetes may damage the blood vessels in the retina. The blood vessels may leak fluid or blood and they may accumulate in the macula and impair vision. This is called the Diabetic Macular Edema (DME).
The following drugs can be used for the treatment of the Diabetic Macular Edema (DME).
A study published in the JAMA Ophthalmology has found that the drug bevacizumab is a cheaper treatment when compared with aflibercept (31 times more expensive) and ranibizumab (20 times more expensive). The aflibercept is the most effective drug for the treatment of Diabetic Macular Edema (DME).
A Treatment For Nonalcoholic Steatohepatitis (NASH) With Pioglitazone
Currently, there are no medical treatment, drug or tablet for the treatment of this disease.
NASH or non-alcoholic steatohepatitis is a silent liver disease caused due to the fat buildup in the liver. NASH can lead to liver cancer (or cirrhosis). The obese people with type 2 diabetes (T2D) are at a higher risk of NASH.
Early diagnosis and treatment are required for this disease. The study was published in the journal Annals of Internal Medicine.
The Risk From Fat Buildup In The Liver (NASH)
About 33 percent of the Americans are obese and it is expected to be 50 percent by 2030.
The Nonalcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease and this disease is associated with diabetes and obesity. The Nonalcoholic Fatty Liver Disease (NAFLD) will be caused due to the accumulation of extra fat in the liver.
A severe form of NAFLD is called Nonalcoholic Steatohepatitis (NASH). The Nonalcoholic Steatohepatitis (NASH) is a "silent" liver disease. The NASH can cause liver inflammation and liver tissue injury and causes serious damage to the liver.
There are no drugs or treatment for the NASH. An individual with high disease risk factors can prevent the disease with lifestyle changes, diet control and regular exercise.
Treatment For Diabetic Eye Disease With Anti-VEGF Injection
A clinical trial shows that the anti-VEGF injection treatment as the prescribed treatment option for the Diabetic Macular Edema (DME).
But a study by Brian L VanderBeek, MD, MPH, a Physician at the Hospital of the University of Pennsylvania, has found that most of the patients were undertreated or not treated early to prevent the development of vision loss.
Patients are taking 3.6 anti-VEGF injections on an average when nine to ten anti-VEGF injections were prescribed.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.